{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":13},"studies":[{"active":true,"description":"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)","eudractNumber":"2024-516066-11-00","id":8116,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":"NCT05009082","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-21T12:11:09+02:00","shortTitle":"AGO-Ovar 28","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"

A First – in Human\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\n764532 administered by repeated intravenous infusions in patients with Small\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

","eudractNumber":"2019-000729-31","id":6385,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"DLL3 (Delta-like 3)","id":"mt_29"}],"nctNumber":"NCT04429087","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2021-10-14T14:19:12+02:00","shortTitle":"BI 1438-0001","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"
A Phase I study to determine the safety and tolerability of BI 3820768 in patient.s with advanced relapsed or refractory germ cell tumours, endometrial cancer, or ovarian cancer
","eudractNumber":"2025-522913-45-00","id":11551,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro3","name":"Hodenkarzinom"}],"mutations":[],"nctNumber":"NCT07306559","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-16T09:36:01+02:00","shortTitle":"BI 2001-0001","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"

A Phase 1/2 Study of BMS-986340 as Monotherapy and in\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors 

EUDRA-CT Nummer geändert 18.12.2023

von 2021-001188-26 auf  2023-503651-10-00

","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T10:18:54+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)","eudractNumber":"2022-501346-30-00","id":9854,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06615479","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-01T09:47:06+02:00","shortTitle":"BMS CA088-1007","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"

A Phase 2 Study to Evaluate the Efficacy and Safety of\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

","eudractNumber":"2020-005028-13","id":7072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT04924075","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-03-01T14:45:17+01:00","shortTitle":"Belzutifan/MK-6482 for the treatment of PPGL or pNET","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients","eudractNumber":"2022-000637-16","id":8358,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR-","id":"mt_50"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05452213","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-11-23T09:18:54+01:00","shortTitle":"CAPTOR-BC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"FUTURE platform trial
A phase II platform trial of futibatinib in combinaton with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
","eudractNumber":"2024-517573-24-00","id":11575,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-12-09T11:05:49+01:00","shortTitle":"FUTURE-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \"PREVENT\" Trial of the AIO /CAOGI /ACO

","eudractNumber":"2017-003832-35","id":6238,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":"NCT04447352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-12-16T12:01:06+01:00","shortTitle":"HIPEC/FLOT9 (PREVENT)","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors","eudractNumber":"2024-513285-19-00","id":10011,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"HRAS","id":"mt_70"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"},{"name":"NRAS","id":"mt_6"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-01T12:28:37+02:00","shortTitle":"KO-2806-001","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]}]},"initialUrl":"/api/studies?lang=de&page=0&size=10&tls=tl_8","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)\",\"name\":\"AGO-Ovar 28\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8116\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A First – in Human\\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\\n764532 administered by repeated intravenous infusions in patients with Small\\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

\",\"name\":\"BI 1438-0001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6385\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase I study to determine the safety and tolerability of BI 3820768 in patient.s with advanced relapsed or refractory germ cell tumours, endometrial cancer, or ovarian cancer
\",\"name\":\"BI 2001-0001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11551\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A Phase 1/2 Study of BMS-986340 as Monotherapy and in\\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors 

EUDRA-CT Nummer geändert 18.12.2023

von 2021-001188-26 auf  2023-503651-10-00

\",\"name\":\"BMS CA052-002\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7045\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)\",\"name\":\"BMS CA088-1007\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9854\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A Phase 2 Study to Evaluate the Efficacy and Safety of\\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

\",\"name\":\"Belzutifan/MK-6482 for the treatment of PPGL or pNET\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7072\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients\",\"name\":\"CAPTOR-BC\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8358\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"FUTURE platform trial
A phase II platform trial of futibatinib in combinaton with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
\",\"name\":\"FUTURE-001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11575\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \\\"PREVENT\\\" Trial of the AIO /CAOGI /ACO

\",\"name\":\"HIPEC/FLOT9 (PREVENT)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6238\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors\",\"name\":\"KO-2806-001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10011\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=1&tls=tl_8\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}